Overview and comparative analysis of the efficacy and safety of current and emerging treatment regimens for diffuse large B-cell lymphoma: implications for future patient outcomes
OA Version
Citation
Abstract
Diffuse large B-cell lymphoma (DLBCL) makes up 30% of non-Hodgkin’s lymphoma (NHL) cases and is widely considered the most common of the NHL subtypes. Most patients are responsive to the 1st-line therapy, R-CHOP; however, 40-50% of cases relapse, are refractory, or completely unresponsive. The available 2nd and 3rd-line therapies include CAR T-cell therapy, salvage ASCT + HDT, immunotherapies, and bispecific monoclonal antibodies, although some 2nd and 3rd-line therapies have modest efficacies, ORR, and CR rates. Moreover, therapies such as CAR T-cell and salvage ASCT + HDT are associated with high-grade AEs and CRS symptoms. In the battle to cure DLBCL, it is imperative to develop treatment options that provide durability while not affecting quality of life. Thus, more targeted therapies such as ADCs, immune checkpoint inhibitors, and novel therapeutic combinations may be key for the future of DLBCL. This thesis provides an overview of the etiology and pathogenesis of DLBCL and comments on the current treatments, their limitations, and the emerging therapies that are promising for the future of DLBCL treatment and outcomes.
Description
2025
License
Attribution-NonCommercial-NoDerivatives 4.0 International